Thrombopoietin receptor agonist (TPO-RA) treatment raises platelet counts and reduces anti-platelet antibody levels in mice with immune thrombocytopenia (ITP) (original) (raw)

Efficacy and Safety of Thrombopoietin Receptor Agonists in Modern Treatment of Immune Thrombocytopenia

2021

A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia

Haematologica, 2013

Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia

Nuria Revilla

Scientific Reports, 2019

View PDFchevron_right

A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia

James Bussel

Blood, 2014

View PDFchevron_right

The role of thrombopoietin receptor agonists in the management of adult primary immune thrombocytopenia - single centre experience

Zlatko Pravdic

Vojnosanitetski pregled, 2021

View PDFchevron_right

Tapering Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia: Recommendations Based on the RAND/UCLA Modified Delphi Panel Method

Howard Liebman

Blood, 2020

View PDFchevron_right

Diagnosis and management of immune thrombocytopenia in the era of thrombopoietin mimetics

Howard Liebman

Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 2011

View PDFchevron_right

Immune Thrombocytopenia : Pathogenesis and Treatment Approaches

Ashok Raj

2017

View PDFchevron_right

Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents

james bussel

Blood, 2010

View PDFchevron_right

Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist

Daphne Williams

Blood, 2007

View PDFchevron_right

Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia

David Aboulafia

Journal of blood medicine, 2016

View PDFchevron_right

Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia

Lee F Allen

British journal of haematology, 2018

View PDFchevron_right

Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia

james bussel

Blood, 2011

View PDFchevron_right

Autoantibodies to thrombopoietin and the thrombopoietin receptor in patients with immune thrombocytopenia

Vanessa D'Souza

British journal of haematology, 2018

View PDFchevron_right

A United Kingdom Immune Thrombocytopenia (ITP) Forum review of practice: thrombopoietin receptor agonists

Nichola Cooper

British Journal of Haematology, 2016

View PDFchevron_right

Phase I Clinical Study of Eltrombopag, an Oral, Non-peptide Thrombopoietin Receptor Agonist

Daphne Williams

2007

View PDFchevron_right

Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia (ITP) patients: A retrospective collaborative survey involving four spanish centers

Fernando Fuerte

European journal of haematology, 2017

View PDFchevron_right

Romiplostim and Eltrombopag in Immune Thrombocytopenia as a Second-Line Treatment

Areeba Memon

Cureus, 2020

View PDFchevron_right

Thrombopoietin receptor agonist antibody for treating chemotherapy-induced thrombocytopenia

sukmook lee

Research Square (Research Square), 2022

View PDFchevron_right

Thrombopoietin as a Drug: Biologic Expectations, Clinical Realities, and Future Directions

mustafa benekli

Clinical and Applied Thrombosis/Hemostasis, 2002

View PDFchevron_right

Re: Risk factors and predictors of treatment responses and complications in immune thrombocytopenia

Kamal Kant Sahu

Annals of Hematology, 2021

View PDFchevron_right

Multiple concomitant mechanisms contribute to low platelet count in patients with immune thrombocytopenia

Nora Goette

Scientific Reports

View PDFchevron_right

Biologic Aspects of Thrombopoietin and the Development of Novel Thrombopoietic Agents for Clinical Use

Maria Nica Evangelista

Current Drug Discovery Technologies, 2007

View PDFchevron_right

Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim

Angela Lopez

International journal of hematology, 2015

View PDFchevron_right

Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists

Waleed Ghanima

British Journal of Haematology, 2012

View PDFchevron_right

Emerging treatments for thrombocytopenia: Increasing platelet production

Jean-marie Stassen, Chris Van Geet

Drug Discovery Today, 2008

View PDFchevron_right

Thrombopoietin therapy increases platelet yields in healthy platelet donors

Jeffrey McCullough

Blood, 2001

View PDFchevron_right

Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus

Ioana Ionita

Annals of Hematology

View PDFchevron_right

Adult Chronic Primary Immune Thrombocytopenia: Safety and Efficacy of Thrombopoietin Receptor Agonists and Rituximab

Cesar Peralta

Journal of Dermatology Research Reviews & Reports, 2021

View PDFchevron_right

11 Thrombopoietin: its role in platelet disorders and as a new drug in clinical medicine

c folman

Baillière's Clinical Haematology, 1998

View PDFchevron_right

Mechanisms of platelet recovery in ITP associated with therapy

Alan Lazarus

Annals of Hematology, 2010

View PDFchevron_right

Autoimmune thrombocytopenia: Current treatment options in adults with a focus on novel drugs

Michał Witkowski

European Journal of Haematology, 2019

View PDFchevron_right

Preclinical Activity of Eltrombopag (SB‐497115), an Oral, Nonpeptide Thrombopoietin Receptor Agonist

Kevin Duffy

Stem …, 2009

View PDFchevron_right

Low platelet counts alone do not cause bleeding in an experimental model of immune thrombocytopenic purpura in mice

Victoria Domínguez

2003

View PDFchevron_right

PLATON: use of romiplostim to treat chronic primary immune thrombocytopenia

Zuzana Sninská

Memo – Magazine of European Medical Oncology, 2020

View PDFchevron_right

Thrombopoietin receptor agonist (TPO-RA) treatment raises platelet counts and reduces anti-platelet antibody levels in mice with immune thrombocytopenia (ITP) (original) (raw)

Related papers